[Topical H1 antihistaminics in the therapy of acute conjunctival allergic reactions].
OBJECTIVE
To determine, whether the immediately originated allergic reaction of conjunctivas may be treated with local H1 antihistaminic drugs in a monotherapy (Allergodil gtt, Emadine gtt).


METHODS
The group included 30 patients at the age of 17 to 40 years at the mean age of 33.2 years, where chemosis and hyperemia of bulbar conjunctiva originated suddenly as well as edema of eyelids. The reported subjective symptoms were itching, burning sensation in the eyes, lacrimation, and the feeling of pressure under the eyelid. Local treatment with azelastin (Allergodil gtt. oph., Pliva), was applied in 15 patients, the other 15 patients were treated locally with emedastin (Emadine gtt. oph., Alcon) at the dose of one drop twice daily into the conjunctival sac of both eyes. The time of onset of the therapeutic effect and the disappearance of subjective symptoms and objective signs were observed.


RESULTS
The disappearance of subjective symptoms after the start of therapy developed within 20 minutes after Allergodil gtt and within 5 minutes after Emadin. Subjective complaints disappeared in the range of 86-100% after Allergodil gtt and in the range of 90-100% after Emadin gtt. A substantial diminution or even complete disappearance of objective symptoms developed in 74-80% cases after the treatment with Allergodil gtt and in 80-87% subjects after Emadin gtt.


CONCLUSIONS
The investigated local H1 antihistaminic drugs proved to be effective in monotherapy of acute phase of allergic conjunctivitis. The drugs influence subjective complaints faster and more efficiently than the objective signs. The therapy of objective manifestations requires longer period of time for the effect to develop.
Haicl
P
P
Ocní klinika VFN a 1. LF UK, Praha.
Cerná
H
H
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009883:Ophthalmic Solutions; D010793:Phthalazines / Q000008:administration & dosage*
D018926:Anti-Allergic Agents; D001562:Benzimidazoles; D006634:Histamine H1 Antagonists; D009883:Ophthalmic Solutions; D010793:Phthalazines; C043345:emedastine; C020976:azelastine